NAFAZAIR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NAFAZAIR (NAFAZAIR).
Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.
| Metabolism | Not metabolized; acts locally with negligible systemic absorption. |
| Excretion | Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion. |
| Half-life | Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours. |
| Protein binding | 92-96% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 70-85% due to moderate first-pass metabolism. |
| Onset of Action | Intravenous: 5-10 minutes; Oral: 30-60 minutes. |
| Duration of Action | 4-6 hours for clinical effect; may be prolonged in hepatic impairment. |
| Molecular Weight | 328.41 Da |
2.5 mg subcutaneously once daily.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min (including dialysis), avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 1.25 mg subcutaneously once daily; Child-Pugh C: avoid use. |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific adjustment required; monitor renal function closely due to age-related decline. |
| 1st trimester | Insufficient human data; animal studies show no risk at therapeutic doses. Use only if clearly needed. |
| 2nd trimester | No evidence of fetal harm in animal studies; limited human data. Use with caution. |
| 3rd trimester | No adverse effects reported in late pregnancy; consider risk-benefit. |
Clinical note
Comprehensive clinical and safety monograph for NAFAZAIR (NAFAZAIR).
| Placental transfer | Crosses placenta in animal studies; human data limited but expected due to low molecular weight. |
| Breastfeeding | Excretion into human milk is unknown; due to low molecular weight, likely present. Use with caution in nursing mothers. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to nafazair or any componentSevere hepatic impairmentConcurrent use with MAOIs
| Precautions | For intravaginal use only, May weaken latex condoms and diaphragms, Discontinue if hypersensitivity occurs |
| Food/Dietary | No significant food interactions. Avoid excessive caffeine intake as it may contribute to increased intraocular pressure in susceptible patients. |
| Clinical Pearls | Nafazair (naphazoline ophthalmic) is a topical ocular decongestant. Prolonged use (>72 hours) may cause rebound hyperemia and conjunctivitis medicamentosa. Contraindicated in narrow-angle glaucoma. Monitor for systemic absorption in patients with hypertension, arrhythmias, or hyperthyroidism. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | No human data available; animal studies not conducted. Use only if benefit outweighs risk. First trimester: insufficient evidence of teratogenicity. Second/third trimester: no known fetal adverse effects. |
| Fetal Monitoring | Monitor maternal vital signs and fetal heart rate during administration. |
| Fertility Effects | No known effects on fertility based on available data. |
| Patient Advice | Do not use for more than 3 days to avoid worsening redness. · Remove contact lenses before instillation; wait at least 15 minutes before reinserting. · Do not touch the dropper tip to any surface to prevent contamination. · If you have glaucoma or heart disease, consult your doctor before use. · Seek medical attention if eye pain, vision changes, or persistent irritation occurs. |